hotspot -WSS

hotspot

author：comprehensive 2025-09-29 13:46:30 - browse：61496

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： CommonSpirit Health keeps growing, even as it loses money

Wikipedia

WSS

How AI helped researchers track recovery from depression

Intarcia’s device

Biotech lab space demand falls sharply

Hearing on Medicare drug price negotiation gets unusually heated

The high personal cost of affirmative action for Black doctors

Pence says 'crackpot lawyers' told Trump what he wanted to hear

focus

hotspot

The next ALS data readout — overdue but important

focus

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: possible new ALS drug, artificial wombs

Medical leaders decry Supreme Court decision on affirmative action

What Congress can do to address the rural doctor shortage

In Memoriam: Notable people who died in 2023

Amazon expands telehealth clinic nationwide

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Psychedelics group wrestles with new pharma identity

Changes to biosimilar regulatory framework must prioritize patients

explore

What Congress can do to address the rural doctor shortage

Amazon expands telehealth clinic nationwide

It's been 20 years since Dolly the sheep. Where's my clone?

Physician groups backed by private equity giant lobby on mergers

Emergency workers more likely to restrain Black patients: study

Physician groups backed by private equity giant lobby on mergers

Wikipedia

entertainment

entertainment

explore